Capecitabine-Reference-Cited by-同舟云学术

Capecitabine

Published:2007-02-01 Issue:2 Volume:12 Page:152-155
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Schellens Jan H.M.¹

Affiliation:

1. The Netherlands Cancer Institute, Amsterdam, The Netherlands, and Utrecht University, Faculty of Science, Department of Pharmaceutical Sciences, Section of Biomedical Analysis, Division of Drug Toxicology, Utrecht, The Netherlands

Abstract

Learning Objectives After completing this course, the reader will be able to: Identify the main toxicity profile associated with capecitabine therapy.Identify the main clinical indications for capecitabine therapy.Identify the populations at risk for severe toxicity from capecitabine therapy. CME Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.com

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.12-2-152

Reference7 articles.

1. Liquid chromatography-mass spectrometry method for the analysis of the anti-cancer agent capecitabine and its nucleoside metabolites in human plasma;Xu;J Chromatogr B Biomed Appl,2003

2. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites;Twelves;Clin Cancer Res,1998

3. Drug interactions in oncology;Beijnen;Lancet Oncology,2004

4. Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients;Giescke;Br J Clin Pharmacol,2003

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of Metronomic Capecitabine in Hepatocellular Carcinoma: A Systematic Review and Meta-analysis;Journal of Gastrointestinal Cancer;2024-08-20

2. Efficacy and Safety of Metronomic Capecitabine in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis;2024-06-09

3. Catalysts of Healing: A Symphony of Synthesis and Clinical Artistry in Small-Molecule Agents for Breast Cancer Alleviation;Molecules;2024-03-05

4. Development of a UPLC-MS/MS assay for the quantitative determination of capecitabine, 5′-deoxy-5-fluorocytidine (5′-dFCR), 5′-deoxy-5-fluorouridine (5′-dFUR), 5′-fluorouracil (5-FU), and α-fluoro-β-alanine (FBAL);PHARMAZIE;2023

5. Assessment of patients’ knowledge of their treatment with capecitabine at the National Institute of Oncology in Rabat;Journal of Oncology Pharmacy Practice;2023-01-13